J Clin Psychopharmacol 2021 Jun 11. Epub 2021 Jun 11.
From the Brain and Mind Centre, Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health Lambert Initiative for Cannabinoid Therapeutics Brain and Mind Centre, School of Psychology, Faculty of Science, The University of Sydney, Sydney, New South Wales Orygen Centre for Youth Mental Health, University of Melbourne, Melbourne, Victoria, Australia.
Background: Cannabidiol (CBD), a major nonintoxicating constituent of cannabis, exhibits anxiolytic properties in preclinical and human studies and is of interest as a novel intervention for treating anxiety disorders. Existing first-line pharmacotherapies for these disorders include selective serotonin reuptake inhibitor and other antidepressants. Cannabidiol has well-described inhibitory action on cytochrome P450 (CYP450) drug-metabolizing enzymes and significant drug-drug interactions (DDIs) between CBD and various anticonvulsant medications (eg, clobazam) have been described in the treatment of epilepsy. Read More